<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2174">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01722669</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000022</org_study_id>
    <nct_id>NCT01722669</nct_id>
  </id_info>
  <brief_title>Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States</brief_title>
  <acronym>PK/PD</acronym>
  <official_title>Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a&#xD;
      single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase.&#xD;
      Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with&#xD;
      evidence of antiphospholipid antibodies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the absorption and activity of quercetin or isoquercetin with or without ascorbic&#xD;
      acid in healthy adults. Oral chews containing quercetin (500mg) or isoquercetin(500 mg total)&#xD;
      with or without ascorbic acid will be given. Pharmacokinetic parameters (AUC, Cmax, Tmax,&#xD;
      elimination half-life) will be determined over 24 hours (8 time points). Pharmacodynamic&#xD;
      inhibition of protein disulfide isomerase activity will also be assessed.&#xD;
&#xD;
      In addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies&#xD;
      will participate. These participants will receive isoquercetin 1000 mg and have&#xD;
      pharmacodynamics studies performed at time 0 and 4 hours.&#xD;
&#xD;
      All study drugs will be provided by Quercegen Pharma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>24 hours</time_frame>
    <description>AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reductase Activity of PDI Using Dieosin Glutathione Disulfide</measure>
    <time_frame>2 hours. Not measured in D</time_frame>
    <description>Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet-induced Thrombin Generation (U/mL)</measure>
    <time_frame>4 hours</time_frame>
    <description>Thrombin induced thrombin generation measured in patient plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Quercetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of quercetin with or without ascorbic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoquercetin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of isoquercetin with or without ascorbic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoquercetin or quercetin</intervention_name>
    <description>Single dose PK/PD study</description>
    <arm_group_label>Isoquercetin</arm_group_label>
    <arm_group_label>Quercetin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subject is willing to participate and provide informed consent&#xD;
&#xD;
          -  Subject is considered reliable and capable of adhering to the protocol per the&#xD;
             judgment of the Investigator&#xD;
&#xD;
          -  Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined&#xD;
             as:&#xD;
&#xD;
               1. Estimated GFR &gt;35 (formula),&#xD;
&#xD;
               2. Platelet count &gt;65 K/uL,&#xD;
&#xD;
               3. Hemoglobin &gt;10.5 grams/dL&#xD;
&#xD;
               4. Total bilirubin &lt;2.0 mg/dL&#xD;
&#xD;
          -  Minimum age 18 years old&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 35 kg/m2&#xD;
&#xD;
          -  For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least&#xD;
             one positive antiphospholipid antibody within the last 8 weeks and/or previous&#xD;
             confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive lupus&#xD;
             anticoagulant ii. anticardiolipin antibody IgM or IgG (&gt;40U GPL) iii. anti-Î²2&#xD;
             Glycoprotein1 antibody titer (&gt;35 units)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to&#xD;
             dosing of quercetin or isoquercetin&#xD;
&#xD;
          -  No history of malabsorptive gastrointestinal disorder&#xD;
&#xD;
          -  Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other&#xD;
             anticoagulants (such as direct thrombin inhibitors or factor X inhibitors)&#xD;
&#xD;
             a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are&#xD;
             permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to&#xD;
             dosing of quercetin/isoquercetin&#xD;
&#xD;
          -  Prescribed niacin for hyperlipidemia&#xD;
&#xD;
          -  Known HIV&#xD;
&#xD;
          -  History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid&#xD;
&#xD;
          -  May not have uncontrolled intercurrent illness including, but not limited to ongoing&#xD;
             or active infection, hepatitis, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris or cardiac arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Zwicker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>November 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2012</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>October 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2020</results_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Jeff Zwicker</investigator_full_name>
    <investigator_title>Associate Professor, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>quercetin</keyword>
  <keyword>isoquercetin</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Contact PI</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 years</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01722669/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quercetin 500mg (ARM A1)</title>
          <description>Single dose PK/PD analyses of quercetin 500 mg</description>
        </group>
        <group group_id="P2">
          <title>Isoquercetin 500mg (ARM B1)</title>
          <description>Single dose PK/PD of isoquercetin 500 mg</description>
        </group>
        <group group_id="P3">
          <title>Quercetin 500 mg + Ascorbic Acid (ARM A2)</title>
          <description>Single dose quercetin with 500 mg + ascorbic acid pk/pd analyses</description>
        </group>
        <group group_id="P4">
          <title>Isoquercetin 500 mg + Ascorbic Acid (ARM B2)</title>
          <description>Single dose isoquercetin 500 mg + ascorbic acid pk/pd analyses</description>
        </group>
        <group group_id="P5">
          <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
          <description>Single dose isoquercetin + 1000 mg ascorbic acid</description>
        </group>
        <group group_id="P6">
          <title>Antiphospholipid Antibody Cohort (ARM D)</title>
          <description>Single dose isoquercetin 1000 mg + 1000 mg ascorbic acid in patients with antiphospholipid antibodies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="8">Antiphospholipid Antibody (ARM D): 6 evaluable and 2 withdrew consent without any data collected</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Measure Analysis Population Description: Antiphospholipid Antibody (ARM D): 2 withdrew consent without any data collected</population>
      <group_list>
        <group group_id="B1">
          <title>Quercetin 500 mg (ARM A1)</title>
          <description>Single dose of quercetin PK/PD analysis</description>
        </group>
        <group group_id="B2">
          <title>Isoquercetin 500 mg (ARM B1)</title>
          <description>Single dose of isoquercetin PK/PD analysis</description>
        </group>
        <group group_id="B3">
          <title>Quercetin 500 mg + Ascorbic Acid (ARM A2)</title>
          <description>Single dose of quercetin + ascorbic acid PK/PD analysis</description>
        </group>
        <group group_id="B4">
          <title>Isoquercetin 500 mg + Ascorbic Acid (ARM B2)</title>
          <description>Single dose of isqouercetin +ascorbic acid PK/PD analysis</description>
        </group>
        <group group_id="B5">
          <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
          <description>single dose isoquercetin + ascorbic acid PK/PD analyses</description>
        </group>
        <group group_id="B6">
          <title>Antiphospholipid Antibody (ARM D)</title>
          <description>single dose isoquercetin +ascorbic acid in patients with antiphospholipid antibodies</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Antiphospholipid Antibody (ARM D): 2 withdrew consent without data collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Antiphospholipid Antibody (ARM D): 2 withdrew consent without data collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Antiphospholipid Antibody (ARM D): 2 withdrew consent without data collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Antiphospholipid Antibody (ARM D): 2 withdrew consent without data collected</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quercetin 500 mg (ARM A1)</title>
            <description>Single dose, measurement of plasma quercetin aglycone</description>
          </group>
          <group group_id="O2">
            <title>Isoquercetin 500 mg (ARM B1)</title>
            <description>Single dose, measurement of plasma quercetin aglycone</description>
          </group>
          <group group_id="O3">
            <title>Quercetin 500 mg + Ascorbic Acid (ARM A2)</title>
            <description>Single dose, measurement of plasma quercetin aglycone</description>
          </group>
          <group group_id="O4">
            <title>Isoquercetin 500 mg + Ascorbic Acid (ARM B2)</title>
            <description>Single dose, measurement of plasma quercetin aglycone</description>
          </group>
          <group group_id="O5">
            <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
            <description>Single dose, measurement of plasma quercetin aglycone</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)</description>
          <units>uM hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.67"/>
                    <measurement group_id="O2" value="15.00" spread="8.94"/>
                    <measurement group_id="O3" value="5.41" spread="2.13"/>
                    <measurement group_id="O4" value="16.34" spread="10.08"/>
                    <measurement group_id="O5" value="40.3" spread="17.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reductase Activity of PDI Using Dieosin Glutathione Disulfide</title>
        <description>Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide)</description>
        <time_frame>2 hours. Not measured in D</time_frame>
        <population>2 hours after oral ingestion</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin 500 mg (ARM A1)</title>
            <description>PDI activity measured by DiESSG assay at 0 and 2 hours</description>
          </group>
          <group group_id="O2">
            <title>Isoquercetin 500 mg (ARM B1)</title>
            <description>PDI activity measured by DiESSG assay at 0 and 2 hours</description>
          </group>
          <group group_id="O3">
            <title>Quercetin 500 mg + Ascorbic Acid (ARM A2)</title>
            <description>PDI activity measured by DiESSG assay at 0 and 2 hours</description>
          </group>
          <group group_id="O4">
            <title>Isoquercetin 500 mg + Ascorbic Acid (ARM B2)</title>
            <description>PDI activity measured by DiESSG assay at 0 and 2 hours</description>
          </group>
          <group group_id="O5">
            <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
            <description>PDI activity measured by DiESSG assay at 0 and 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Reductase Activity of PDI Using Dieosin Glutathione Disulfide</title>
          <description>Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide)</description>
          <population>2 hours after oral ingestion</population>
          <units>Percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="24.14"/>
                    <measurement group_id="O2" value="63.2" spread="25.3"/>
                    <measurement group_id="O3" value="16" spread="31.8"/>
                    <measurement group_id="O4" value="8.3" spread="15.03"/>
                    <measurement group_id="O5" value="38" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet-induced Thrombin Generation (U/mL)</title>
        <description>Thrombin induced thrombin generation measured in patient plasma</description>
        <time_frame>4 hours</time_frame>
        <population>4 hours after single dose only measured in Arm C and Arm D</population>
        <group_list>
          <group group_id="O1">
            <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
            <description>Thrombin induced thrombin generation measured before and after isoquercetin + Ascorbic acid at time 0 and 4 hours</description>
          </group>
          <group group_id="O2">
            <title>Antiphospholipid Antibody (ARM D)</title>
            <description>Thrombin induced thrombin generation measured at time 0 and 4 hours following isoquercetin 1000 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet-induced Thrombin Generation (U/mL)</title>
          <description>Thrombin induced thrombin generation measured in patient plasma</description>
          <population>4 hours after single dose only measured in Arm C and Arm D</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread=".28"/>
                    <measurement group_id="O2" value="1.40" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed during visit 1, up to 24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quercetin 500 mg (ARM A1)</title>
          <description>Toxicity over 24 hours following single dose</description>
        </group>
        <group group_id="E2">
          <title>Isoquercetin 500 mg (ARM B1)</title>
          <description>Toxicity over 24 hours following single dose</description>
        </group>
        <group group_id="E3">
          <title>Quercetin 500 mg + Ascorbic Acid (ARM A2)</title>
          <description>Toxicity over 24 hours following single dose of combined quercetin and ascorbic acid</description>
        </group>
        <group group_id="E4">
          <title>Isoquercetin 500 mg + Ascorbic Acid (ARM B2)</title>
          <description>Toxicity over 24 hours following single dose of combined isoquercetin and ascorbic acid</description>
        </group>
        <group group_id="E5">
          <title>Isoquercetin 1000 mg + Ascorbic Acid (ARM C)</title>
          <description>Toxicity over 24 hours following single dose of isoquercetin</description>
        </group>
        <group group_id="E6">
          <title>Antiphospholipid Antibody (ARM D)</title>
          <description>Toxicity over 24 hours following single dose of isoquercetin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Zwicker, Division of Thrombosis and Haemostasis, Division of Hematology and Oncology</name_or_title>
      <organization>Beth Israel Deaconess Medical Center, Harvard Medical School</organization>
      <phone>617-667-9299</phone>
      <email>jzwicker@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

